Supplementary Table S2 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Table S2 shows the light stability of free drugs</p

Characterization of ADCs from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

HPLC-HIC, LC-MS, HPLC-SEC, residual free drug analysis, and endotoxin levels of ADCs</p

Synthetic Procedures from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Synthesis and characterization of free drugs and drug-linkers</p

Supplementary Table S1 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Table S1 shows the in vitro cytotoxicity of free drugs</p

Supplementary Table S3 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Table S3 shows the DMPK properties of lead payloads</p

Supplementary Figure S1 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Figure S1 shows the murine plasma stability of T-DL4 and T-DL13</p

Supplementary Figure S3 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Figure S3 shows the in vitro cytotoxicity assessment of trastuzumab-ADCs in both two-dimensional (2D) and three-dimensional (3D) spheroid assays</p

Supplementary Figure S2 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Figure S2 shows the chemical stability of FD1 (ZD06519)</p

Supplementary Figure S4 from Design and Evaluation of ZD06519, a Novel Camptothecin Payload for Antibody Drug Conjugates

Supplementary Figure S4 shows the pharmacokinetic analysis of ADCs (total antibody PK) from the tolerability study in rats</p